Ballew Advisors Inc Buys 5,750 Shares of Danaher Corporation $DHR

Posted by Brian Himes on Oct 5th, 2026

Ballew Advisors Inc purchased a new stake in Danaher Corporation (NYSE:DHR – Free Report) during the third quarter, according to its most recent filing with the SEC. The fund purchased 5,750 shares of the conglomerate’s stock, valued at approximately $1,274,000.

Several other hedge funds have also bought and sold shares of DHR. BlackRock Inc. bought a new stake in shares of Danaher in the second quarter worth about $10,492,520,000. Jupiter Topco LLC bought a new position in Danaher during the second quarter valued at approximately $1,456,317,000. Generation Investment Management LLP purchased a new position in Danaher during the 2nd quarter valued at approximately $1,287,949,000. Bank of America Corp DE purchased a new position in Danaher during the 2nd quarter valued at approximately $993,846,000. Finally, Legal & General Group Plc bought a new stake in Danaher in the 2nd quarter worth approximately $801,056,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Trading Up 3.2%

NYSE DHR traded up $6.82 on Monday, hitting $220.88. 3,093,258 shares of the stock were exchanged, compared to its average volume of 4,466,791. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. The stock has a fifty day moving average price of $209.20 and a two-hundred day moving average price of $193.70. The firm has a market capitalization of $155.28 billion, a P/E ratio of 39.23, a P/E/G ratio of 2.67 and a beta of 0.76. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80.

Danaher (NYSE:DHR – Get Free Report) last announced its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. During the same quarter in the prior year, the firm posted $0.77 earnings per share. The business’s revenue for the quarter was up 5.5% on a year-over-year basis. Research analysts forecast that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a dividend of $0.40 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. Danaher’s dividend payout ratio is currently 28.42%.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Wells Fargo & Company decreased their price objective on Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 22nd. UBS Group initiated coverage on shares of Danaher in a research report on Wednesday, September 9th. They issued a “buy” rating and a $250.00 price target on the stock. Guggenheim upped their price target on shares of Danaher from $200.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday. Piper Sandler started coverage on shares of Danaher in a research note on Thursday, June 11th. They issued a “neutral” rating and a $200.00 price objective for the company. Finally, TD Cowen reduced their target price on shares of Danaher from $240.00 to $236.00 and set a “buy” rating on the stock in a report on Wednesday, July 22nd. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $234.09.

Get Our Latest Report on Danaher

About Danaher

(Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.